Traders just won’t give up on Luckin Coffee (OTCMKTS:LKNCY). The one-time apparent Starbucks (NASDAQ:SBUX) of China, Luckin stock lost more than 90% of its value this year following revelations of fraud. Source: abolukbas / Shutterstock.com Luckin vastly inflated its reported sales. On the basis of these inaccurate numbers, Luckin sold stock to the public at artificially
0 Comments
For years, Under Armour (NYSE:UAA) has been an eyesore in the otherwise burgeoning athletic apparel market, and Under Armour stock has paid the price. Over the past five years — while Nike (NYSE:NKE) stock has risen 100%, Adidas (OTCMKTS:ADDYY) stock has risen 300% and Lululemon (NASDAQ:LULU) stock has risen 600% — Under Amour has lost
0 Comments
Shares of Vertex (VRTX) declined 20% last week after the company announced the discontinuation of VX-814, the company’s candidate for alpha-1 antitrypsin deficiency. The decline seems disproportionate to the perceived value of this program, but it underscores Vertex’s main weakness – its relatively early-stage and unproven pipeline outside of cystic fibrosis (CF). The stock looks
0 Comments
In my last piece discussing Inovio (NASDAQ:INO) stock, I mentioned reasons to remain positive on the biotech company despite a sharp pullback recently. But it looks like Inovio’s chances for mounting a comeback are slowly slipping away. Source: Ascannio / Shutterstock.com The markets have spoken. They want something concrete from the biotech company before they can
0 Comments
(L-R) Lloyd Blankfein and David Solomon attend NYSCF Annual Summer Cocktail Reception at Private Residence on July 15, 2016 in Sagaponack, NY. Sean Zanni | Patrick McMullan | Getty Images Goldman Sachs is moving to claw back tens of millions of dollars in compensation it’s paid executives including CEO David Solomon and former CEO Lloyd
0 Comments